Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L22 pseudogene 20 (RPL22P20)
- Target
- RPL22P20
- Molecular classification
- Other, Pseudogene
01
Overview
Ribosomal protein L22 pseudogene 20 (RPL22P20) is a processed pseudogene related to the ribosomal protein L22 gene (RPL22). Pseudogenes such as RPL22P20 are non-functional copies of protein-coding genes that arise during genomic evolution and typically do not encode functional proteins. While the parent gene RPL22 is a component of the large ribosomal 60S subunit and is involved in protein synthesis and implicated in several cancers and biological processes, there is no evidence that RPL22P20 itself is functional, serves as a therapeutic target, or is involved in disease. Pseudogenes may in rare cases have regulatory RNA roles, but no such activities have been described for RPL22P20 in the available literature.
- Other names
- RPL22P20RPL22_10_1337
02
Mechanism of action
None
03
Biological functions
Other (Pseudogenes are generally non-functional copies of genes, though some may have regulatory roles. There is no evidence in the provided results that RPL22P20 encodes a functional protein or has a defined biological function)
04
Disease associations
Other (No direct evidence links RPL22P20 to any disease role; disease associations discussed in the results pertain to the parent gene RPL22, but not to the pseudogene RPL22P20)
05
Safety considerations
None known
06
Interacting drugs
None known
07
Biomarkers
None known
Beyond the preview
Go deeper on Ribosomal protein L22 pseudogene 20 (RPL22P20).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L22 pseudogene 20 (RPL22P20).